title: Fatal recurrence of autoimmune hemolytic anemia following pentostatin therapy in a patient with a history of fludarabine-associated hemolytic anemia.
authors.affiliation: Department of Medicine, Walter Reed Army Medical Center, Washington, DC, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Byrd
authors.forename: A A
authors.initials: AA
authors.lastname: Hertler
authors.forename: R B
authors.initials: RB
authors.lastname: Weiss
authors.forename: J
authors.initials: J
authors.lastname: Freiman
authors.forename: S L
authors.initials: SL
authors.lastname: Kweder
authors.forename: L F
authors.initials: LF
authors.lastname: Diehl
mesh_terms: D000743:Anemia, Hemolytic / Q000139:chemically induced*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001327:Autoimmune Diseases / Q000139:chemically induced*; D017809:Fatal Outcome; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D015649:Pentostatin / Q000009:adverse effects*; D012008:Recurrence; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D000970:Antineoplastic Agents; D015649:Pentostatin; D014740:Vidarabine; C024352:fludarabine